The objective of this retrospective study (N = 169) was to compare the overall survival (OS) of different subtypes of mantle cell lymphoma (MCL) treated by the Nebraska Lymphoma Study Group between 1984 and 2012. The overall response rate to various therapies including stem cell transplant (SCT) was similar (p = 0.44) between blastoid, diffuse and nodular subtypes. At 5 years, blastoid and diffuse subtypes had worse OS (overall p = 0.005) compared to nodular subtype. In multivariate analysis, the blastoid and diffuse subtypes had similar risk of death (p = 0.14) whereas the nodular subtype had a lower risk compared to blastoid (HR 0.48, 95% CI 0.27-0.87, p = 0.01). The use of SCT was associated with lower risk of death. In univariate analysis, blastoid subtype had better OS with intensive upfront therapy. In conclusion, the OS of blastoid subtype is worse than nodular MCL but may improve with the use of SCT and probably intensive induction therapy.

Original languageEnglish (US)
Pages (from-to)1327-1334
Number of pages8
JournalLeukemia and Lymphoma
Issue number6
StatePublished - Jun 2 2016


  • Blastoid variant
  • diffuse subtype
  • intensive induction therapy
  • mantle cell lymphoma
  • nodular subtype
  • stem cell transplantation

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Clinicopathologic features, management and outcomes of blastoid variant of mantle cell lymphoma: A Nebraska Lymphoma Study Group Experience'. Together they form a unique fingerprint.

  • Cite this